PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Paz-Ares, Luis G., de Marinis, Filippo, Dediu, Mircea, Thomas, Michael, Pujol, Jean-Louis, Bidoli, Paolo, Molinier, Olivier, Sahoo, Tarini Prasad, Laack, Eckart, Reck, Martin, Corral, Jesús, Melemed, Symantha, John, William, Chouaki, Nadia, Zimmermann, Annamaria H., Visseren-Grul, Carla, Gridelli, Cesare·2013·Journal of Clinical Oncology
DOI 10.1200/jco.2012.47.1102

Cited by (622)

Items 501–600 of 622

  1. Lung Cancer
    Solange Peters, Stefan Zimmermann · 2018 · Springer eBooks
  2. Lung Cancer
    Guy Berchem, Solange Peters · 2024 · Springer eBooks
  3. Lungenkarzinom
    David Felix Heigener, Martin Reck · 2017 · Der Internist
  4. Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series
    Raffaella Palumbo, Luca Licata, Federico Sottotetti, Barbara Tagliaferri, Emma Pozzi, Cristina Maria Teragni, Erica Quaquarini, Antônio Bernardo · 2018 · Oncology Research and Treatment
  5. A Case of Adenoid Cystic Carcinoma of the Lung That Was Effectively Treated with Pemetrexed for a Long Period After Combination Chemotherapy with Platinum Doublet and Pemetrexed
    Ayano Toriyama, Michiharu Suga, Angyoung Kang, Yasukiyo Nakamura, Chihiro Watanabe, Hideo Kita · 2018 · Haigan
  6. Prolonged survival with maintenance pemetrexed for a multiple primary malignancy
    Md Shuayb, Md Salim Reza · 2018 · BMJ Supportive & Palliative Care
  7. Management of Advanced Non–Small Cell Lung Cancer
    Bing Xia, Roy S. Herbst · 2018 · Elsevier eBooks
  8. First-Line Therapy for Wild-Type Patients
    Michael J. Jelinek, Jyoti D. Patel · 2018 · Elsevier eBooks
  9. Durable Response After 2 Doses of Pembrolizumab in a Patient With Non–Small-Cell Lung Cancer With an Isolated Brain Metastasis
    Dipesh Uprety, Lubina Arjyal, Yazhini Vallatharasu, Amir Bista, Richard J. Wittchow, David E. Marinier · 2019 · Clinical Lung Cancer
  10. Comparison between two premedication regimens of dexamethasone before a pemetrexed-based chemotherapy: A single-center experience study
    Andréanne Groleau, Jimmy Côté · 2019 · Journal of Oncology Pharmacy Practice
  11. Tolerance and efficacy of branded generic pemetrexed maintenance in Indian patients of metastatic non-squamous non-small-cell lung cancer
    Amit Sehrawat, K M Parthasarathy, Deni Gupta, Arun Gera · 2019 · Indian Journal of Cancer
  12. Immunothérapie et tumeurs oligométastatiques
    Thierry Berghmans · 2020 · Revue des Maladies Respiratoires Actualités
  13. A retrospective study on pemetrexed induced nephrotoxicity in non-small cell lung carcinoma patients
    Kallem Sharat Venkat Reddy, Harichandana Punukula, C. Bhavya, Narender Kumar Thota · 2021 · International Journal of Basic & Clinical Pharmacology
  14. Chemotherapy
    Adam P. Januszewski, Sanjay Popat · 2015 · European Respiratory Society eBooks
  15. Immunotherapy
    Takahiro Ebata · 2017 · Springer eBooks
  16. The Impact of The Immune Check Point on Cost in Lung Cancer: Duration of use
    Helmy M. Guirgis · 2022 · Medical Research Archives
  17. Prolonged survival with first-line chemotherapy in advanced extrahepatic cholangiocarcinoma
    Chrystle Mascarenhas, D'souza Sanyo · 2023 · BMJ Case Reports
  18. Studio PARAMOUNT: significato clinico della continuous maintenance therapynel tumore del polmone
    Cesare Gridelli · 2015 · Recenti Progressi in Medicina
  19. Reply to S. Barni et al, K.R. Dearing et al, and N. Murray
    Luis G Paz-Ares, Filippo de Marinis, Carla Visseren‐Grul, Cesare Gridelli · 2014 · Journal of Clinical Oncology
  20. Management of cancer of the lung
    Alison E. Brewster, Fergus R Macbeth · 2015 · Cambridge University Press eBooks
  21. First-line cytotoxic chemotherapy regimen for non-small cell lung cancer in the elderly population: plus ca change
    Grace Kho Dy, Maya Khalil, Edwin H. Yau · 2020 · Translational Lung Cancer Research
  22. Management of Advanced Disease in NSCLC
    A.E. Davies, Martin David Forster · 2021 · Elsevier eBooks
  23. Expectations in the Care of Lung Cancer
    Rogério Lilenbaum, Natasha B. Leighl, M. Neubauer · 2015 · American Society of Clinical Oncology Educational Book
  24. Malignome des Respirationstrakts
    Alexander H. Schmittel · 2012 · Elsevier eBooks
  25. Cáncer de pulmón de célula no pequeña ALK positivo. Prevalencia y características. La inmunohistoquímica como método diagnóstico.
    Pablo Martínez · 2015 · TDX (Tesis Doctorals en Xarxa)
  26. Prognosis, Prediction and Risk Assessment in the Prevention and Treatment of Non-Small Cell Lung Cancer
    Martin Sandelin · 2015 · KTH Publication Database DiVA (KTH Royal Institute of Technology)
  27. Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study
    Armando Santoro, Gunnar Hillerdal, Gert Hoeffken, Adolfo Gino Favaretto, R.P. Carrion, Carla Visseren‐Grul, Sophie Ameryckx, Karin Helsberg, Victoria Soldatenkova, Nawel Bourayou et al. · 2014 · Lung Cancer
  28. Reply to B.M. Strebel
    Fabrice Barlési, Arnaud Scherpereel, Achim Rittmeyer, Antonio Pazzola, Joo-Hang Kim, Myung‐Ju Ahn, Joachim G.J.V. Aerts, Anders Vikström, Harry J.M. Groen · 2013 · Journal of Clinical Oncology
  29. Second Line in NSCLC: New Opportunities?
    Antônio Rossi, Domenico Galetta · 2015 · Lung Cancer Management
  30. Stratégie de maintenance dans les carcinomes bronchiques non à petites cellules de stade IV
    Vincent Bunel, Maurice Pérol · 2014 · Revue des Maladies Respiratoires Actualités
  31. Ramucirumab: a promising development in advanced non-small cell lung cancer
    Virginie Avrillon, Maurice Pérol · 2014 · Clinical Investigation
  32. Second-line options for EGFR- and Alk-unmutated lung cancers Therapeutic decisionmaking in the molecular era
    Normand Blais · 2014
  33. The PARAMOUNT trial in NSCLC: is the amount of benefit clinically meaningful?
    Fausto Petrelli, Sandro Barni · 2013 · PubMed
  34. Traitement de 1re ligne des cancers bronchopulmonaires non à petites cellules de stade IV en l'absence d'addiction oncogénique
    Maurice Pérol, Virginie Avrillon · 2015 · Revue des Maladies Respiratoires Actualités
  35. Antiangiogéniques en cancérologie thoracique : critères de prescription et gestion des effets indésirables
    Solenn Brosseau, Charles Naltet, Valérie Gounant, Gérard Zalcman · 2015 · Revue des Maladies Respiratoires Actualités
  36. [Treatment progress for EGFR wild-type advanced non-small cell lung cancer].
    Feng Ma, Xiaoyu Shi, Wei Meng, Jing Zhang, Lixia Zhao, Xiaohua He, Junfeng Zhao · 2014 · Europe PMC (PubMed Central)
  37. Finale Ergebnisse: Längeres Überleben bei fortgeschrittenem NSCLC durch Pemetrexed
    Andreas Fischer · 2013 · Im Focus Onkologie
  38. A Retrospective Study of Combination Chemotherapy with Cisplatin Plus Pemetrexed as a First-line Therapy for Advanced Non-squamous Non-small Cell Lung Cancer
    Toshiya Inui, Takuma Yokoyama, Saori Takata, Aya Hirata, Tomotaka Nishizawa, Ichiro Hirukawa, Hiroo Wada, Haruyuki Ishii, Hajime Takizawa, Hajime Goto · 2014 · Haigan
  39. Maintenance Therapy for Advanced Non–Small-Cell Lung Cancer
    Anne S. Tsao · 2013 · Journal watch
  40. 3. Chemotherapy for Patients with Non-small Cell Lung Cancer, 1) Cytotoxic Drug Treatment, Maintenance Therapy, and Secondary Line Treatment
    Kazuhisa Takahashi · 2014 · Nihon Naika Gakkai Zasshi
  41. Positiver Effekt auf das Überleben
    Andreas Schalhorn · 2013 · Info Onkologie
  42. Les populations particulières : les personnes âgées atteintes d’un cancer bronchique
    C. Leduc, B. Mennecier, A Ducoloné, C. Matau, P. Fraisse, Élisabeth Quoix · 2016 · Revue des Maladies Respiratoires Actualités
  43. Traitement de seconde ligne et au-delà des cancers bronchopulmonaires non à petites cellules de stade IV en l’absence d’addiction oncogénique
    Maurice Pérol, Valérie Paulus, Virginie Avrillon · 2016 · Revue des Maladies Respiratoires Actualités
  44. A Case of Salvage Surgery for Lung Cancer After 40 Courses of Pemetrexed Maintenance Therapy for 3 Years Following the Treatment of Brain Metastases
    Shigeaki Iwatsubo, Michinobu Hashimoto, Tomoko Nishimura, Takashi Nishimura, Yasuji Terada, Yumiko Yasuhara · 2016 · Haigan
  45. A challenge to overcome: the maintenance of the global quality of life in patients with advanced or metastatic non-small cell lung cancer
    Simona Carnio, Silvia Novello · 2016 · Expert Review of Quality of Life in Cancer Care
  46. Adding chemotherapy to TKI: can we improve first-line treatment for EGFR-mutated NSCLC patients?
    Francesco Passiglia, Antonio Russo · 2016 · Translational Cancer Research
  47. Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: uaktualnione zalecenia ekspertów
    Jacek Jassem, Wojciech Biernat, Maciej Bryl, Joanna Chorostowska‐Wynimko, Rafał Dziadziuszko, Paweł Adam Krawczyk, Radzisław Kordek, Dariusz Mirosław Kowalski, Maciej Jerzy Krzakowski, Wlodzimierz Tadeusz Olszewski et al. · 2014 · Nowotwory Journal of Oncology
  48. Advancing the Management of Non-small Cell Lung Cancer
    David F Fakih · 2017 · European Oncology & Haematology
  49. Current Status and Future Perspective on Cytotoxic Agents for Squamous Cell Carcinoma of the Lung
    Hiroshige Yoshioka · 2015 · Haigan
  50. Radio-Immunotherapy: A Promising Weapon to Consider in the Fight against NSCLC
    Christian Caglevic, B. Tudela, Gallardo Carlos E, A Cardona-Ospina Jaime, Sergio Panay, Mauricio Mahave, Hugo Raul Marsiglia · 2017 · International Journal of Radiology & Radiation Therapy
  51. Exploring immunogenomic influences on the microenvironment of colorectal cancer
    Neeraj Lal · 2017 · University of Birmingham Institutional Research Archive (University of Birmingham)
  52. What’s new in chemotherapy for non-small cell lung cancer?
    Christian Britschgi · 2017 · memo - Magazine of European Medical Oncology
  53. Traitement de première ligne et de maintenance dans les CBNPC avancés en l’absence d’addiction oncogénique
    Maurice Pérol, Valérie Paulus, Aurélie Swalduz, Virginie Avrillon · 2017 · Revue des Maladies Respiratoires Actualités
  54. Genetic biomarkers of chemotherapy response and resistance in lung cancer patients
    D. Nelmes · 2018 · ORCA Online Research @Cardiff (Cardiff University)
  55. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)
    Taichi Takashina, Hajime Asahina, Satoshi Oizumi, Noriyuki Yamada, Masao Harada, Kei Takamura, Hiroshi Yokouchi, Toshiyuki Harada, Osamu Honjo, Takahiro Ogi et al. · 2018 · International Journal of Clinical Oncology
  56. Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
    Nicolas Marcoux, Lecia Van Dam Sequist · 2018 · Elsevier eBooks
  57. Chimiothérapie de première ligne incluant le traitement de maintenance et les anti-angiogéniques dans les CBNPC avancés en l’absence d’addiction oncogénique
    Maurice Pérol, Aurélie Swalduz, Valérie Paulus, Virginie Avrillon · 2018 · Revue des Maladies Respiratoires Actualités
  58. Maintenance Chemotherapy for Nonsmall Cell Lung Cancer
    Maurice Pérol, Heather A. Wakelee, Luis G Paz-Ares · 2018 · Elsevier eBooks
  59. Medikamentöse Therapie des metastasierten oder rezidivierten mutationsnegativen NSCLC
    Achim Rittmeyer · 2019 · Wiener klinisches Magazin
  60. Traitements de première ligne dans les CBNPC avancés, en l’absence d’addiction oncogénique (incluant le traitement de maintenance et les anti-angiogéniques)
    Solenn Brosseau, Valérie Gounant, Aurélie Swalduz, Virginie Avrillon, Maurice Pérol, Gérard Zalcman · 2019 · Revue des Maladies Respiratoires Actualités
  61. Radiologic Complete Response In Lung Adenocarcinoma With Symptomatic Brain Metastasis After Systematic Therapy: A Case Study
    Jianxin Chen, Junhui Wang, Qinhong Zheng, Meiling Weng, Xilin Wu · 2019 · OncoTargets and Therapy
  62. Primary lung cancer metastatic to the breast: case report of a patient in remission
    Pedro Marchiori Cacilhas, Kelly Mallmann Silva, Monique Wickert, Allan Arrieira Azambuja · 2019 · Brazilian Journal of Oncology
  63. A Case of Pulmonary Adenocarcinoma with Amylase Production
    Nozomi Tani, Akihiro Yoshimura, Sachi Harita, Mototaka Fukui, Tadaaki Yamada, Koichi Takayama · 2020 · Haigan
  64. Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801
    Koichi Takayama, Masafumi Takeshita, Koji Inoue, Masao Ichiki, Masaki Fujita, Taishi Harada, Yoshimasa Shiraishi, Hiroshi Wataya, Shoji Tokunaga, Tadaaki Yamada et al. · 2020 · The Oncologist
  65. Diagnostic and therapeutic guidelines for stage III non-small-cell lung cancer
    Gabriela Krákorová · 2016 · Onkologie
  66. Maintaining Equipoise With Maintenance Therapy in Mesothelioma
    Aaron Scott Mansfield · 2020 · Clinical Lung Cancer
  67. A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC
    Xiaoxin Lu, Shengshu Li, Weizong Chen, Dongyang Zheng, Yuzhu Li, Fang Li · 2020 · Medicine
  68. Traitements systémiques de première ligne dans les CBNPC avancés en l’absence d’addiction oncogénique
    Maurice Pérol, Aurélie Swalduz, Virginie Avrillon, Valérie Gounant, Solenn Brosseau, Gérard Zalcman · 2020 · Revue des Maladies Respiratoires Actualités
  69. Clinical observation of Pemetrexed first-line treatment in advanced non-squamous lung cancer or non-small cell lung cancer without driver-mutations: a phase 2, single-arm trial
    Zhou Sha, Jianbo He, Qinling Jiang, Linlin Xu, Liyang Hu, Zibin Liang, Tin Li, Lin Zhong, Qitao Yu, Pei X et al. · 2020 · Annals of Translational Medicine
  70. Cytotoxic Chemotherapy in the Era of Immunotherapy for Lung Cancer
    Satoru Miura · 2020 · Haigan
  71. Recomendaciones de oncólogos que trabajan en el ISSSTE para el tratamiento sistémico del cáncer de pulmón avanzado 2020
    Fernando Aldaco-Sarvide, Aura A. Erazo Valle-Solís, David Neri Acosta-Gutiérrez, Denisse Añorve-Bailón, Diego Alfonso Ballesteros-Pino, Guadalupe Cervantes-Sánchez, Eduardo Cárdenas-Cárdenas, Juan Carlos Cruz-López, Maria Guadalupe Díaz-Alvarado, Carolina Durán-Gil et al. · 2020 · Latin American Journal of Clinical Sciences and Medical Technology
  72. Long-Term Tolerability and Efficacy of Carboplatin/Pemetrexed as Maintenance Therapy for a Patient With Lung Adenocarcinoma
    Lixia Ju, Juan Yang · 2021 · Research Square
  73. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib
    Noemı́ Reguart, Roxana Reyes · 2021 · touchREVIEWS in Oncology & Haematology
  74. What if Bevacizumab was discontinued! Can IMpower130 be exchanged for IMpower150 for advanced non-squamous NSCLC patients with PD-L1 <50% and without genomic mutations?
    Khaled Omran · 2021 · World Journal of Advanced Research and Reviews
  75. Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial
    Pierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, Alexis Benjamin Cortot, J. Margery, Lionel Moreau, R. Gervais, Fabrice Barlési, Éric Pichon, Gérard Zalcman et al. · 2021 · Lung Cancer
  76. Biomarker Troponin (1): Das diagnostische Potenzial ist noch nicht ausgeschöpft
    Dustin Grunert · 2017 · Deutsches Ärzteblatt
  77. Epidemiological, Clinical Profile, and Treatment Outcome of Stage IV Nonsquamous Nonsmall Cell Lung Cancer Patients Presenting to Tertiary Care Hospital in North India
    Venkata Pradeep Babu Koyyala, Manish R. Sharma, Pankaj Goyal, Varun Goel, Sravya Bommera, Mohit Agrawal, Kshitiz Domadia, Krushna Choudhary, Sneha Jatan Bothra, Ankush Jajodia et al. · 2021 · Oncology Journal of India
  78. Lung Cancer
    Francesco Passiglia, Valerio Gristina, Christian Diego Rolfo, Nadia Barraco, Viviana Bazan, Antonio Dello Russo · 2021 · UNIPA Springer series
  79. Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis
    Yaru Tian, Hairong Tian, Xiaoyang Zhai, Hui Zhu, Jinming Yu · 2022 · Frontiers of Medicine
  80. Malignome des Respirationstrakts
    Alexander H. Schmittel · 2017 · Elsevier eBooks
  81. E28 Literaturhinweise und Internetadressen
    2015 · Elsevier eBooks
  82. The Impact of The Immune Check Point Duration of use on Cost in Lung Cancer
    Helmy M. Guirgis · 2022 · Pharmaceutics and Pharmacology Research
  83. Available Immunotherapy Drugs in Oncology
    Valerio Gristina, Federica Iacono, Maria Chiara Lisanti, Maria La Mantia, Antonio Galvano · 2022 · Current clinical pathology
  84. Folate Antagonists
    Lisa M. Gennarini, Peter D. Cole, Joseph R. Bertino · 2022 · Holland‐Frei Cancer Medicine
  85. Cancer of the Lung
    Daniel Morgensztern, Daniel J. Boffa, Alexander Junxiang Chen, Andrew P. Dhanasopon, Sarah B. Goldberg, Roy H. Decker, Siddhartha H. K. Devarakonda, Jane P. Ko, Luisa M. Solis Soto, Saiama Naheed Waqar et al. · 2022 · Wiley eBooks
  86. Frontiers in Non-metastatic, Muscle-invasive Bladder Cancer
    Kana T Lucero, James Yoo, Chethan Ramamurthy · 2022 · touchREVIEWS in Oncology & Haematology
  87. Datele din lumea reală şi studiile clinice pentru evaluarea eficacităţii noilor terapii oncologice. Rolul studiilor observaţionale, cu exemplificare în cancerul pulmonar fără celule mici (NSCLC)
    Mihaela Teodorescu, Alexandru Călin Grigorescu · 2022 · Oncolog-Hematolog ro
  88. Treatment and survival status of patients with EGFR mutation-positive stage IV lung adenocarcinoma: five-year follow-up results in the Ordos Area of Inner Mongolia, China*
    Gaowa Jin, Wenjuan Wang, Shuqin Deng, Caihong Jiang, Xiaojun Bai, Jun Zhao, Feng Chen, Jixiang Hou, Lanzhen Zhao, Hui Li et al. · 2018 · Oncology and Translational Medicine
  89. Data from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
    Joel Robert Eisner, Gregory M. Mayhew, James M. Davison, Kirk D. Beebe, Yoichiro Shibata, Yuelong Guo, Carol J. Farhangfar, Farhang Farhangfar, Joshua M. Uronis, Jeffrey M. Conroy et al. · 2023
  90. Data from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
    Joel Robert Eisner, Gregory M. Mayhew, James M. Davison, Kirk D. Beebe, Yoichiro Shibata, Yuelong Guo, Carol J. Farhangfar, Farhang Farhangfar, Joshua M. Uronis, Jeffrey M. Conroy et al. · 2023
  91. Folate Antagonists
    Peter D. Cole, Lisa M. Figueiredo, Joseph R. Bertino · 2017 · Holland‐Frei Cancer Medicine
  92. Non-small Cell Lung Cancer
    Celal Satıcı, Ufuk Yılmaz · 2023 · Springer eBooks
  93. First-line therapy
    Marie-Pier Gauthier, Natasha B. Leighl · 2023 · Elsevier eBooks
  94. Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study
    María José Juan-Fita, Urbano Anido, María José Méndez-Vidal, Regina Gironés Sarrió, José Muñoz-Langa, Juan Manuel Sepúlveda-Sánchez, Begoña Mellado, Carlos Álvarez-Fernández, Lucía Heras López, José Antonio López‐Guerrero et al. · 2023 · Cancers
  95. Optimal Front-Line Therapy for Non-Oncogene-Driven Non-Small Cell Lung Cancer
    Shipra Maheshwari, Ryan D. Gentzler · 2024 · Advances in Oncology
  96. The Efficacy and Toxicity of Maintenance Therapy with Pd-1/Pd-L1 Inhibitors Plus Pemetrexed Versus Immunotherapy Alone for Stage Iii/Iv Non-Squamous Non-Small Cell Lung Cancer: A Real World Study
    Zijian Huang, Shi‐Qi Mei, Jiaqi Liu, Qiuyi Zhang, Jianhua Chang, Zhihua Li, Jingyan Xu, Wei‐Chi Luo, Chang Lu, Chan-Yuan Zhang et al. · 2024 · SSRN Electronic Journal
  97. Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study
    Wei Fang, Xingqiao Peng, Qun Zhou · 2024 · Journal of Cardiothoracic Surgery
  98. “Tumor-Free Survival” Outweighs the Side Effects of Combined Anti-EGF Therapy and Chemotherapy in Patients With NSCLC
    Maisam Makarem, Pasi Antero Janne · 2024 · Journal of Thoracic Oncology
  99. Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-Line Platinum-Based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05)
    Inkeun Park, Shinkyo Yoon, Il Hwan Kim, Kwonoh Park, Suee Lee, Bhumsuk Keam, Joo-Hwan Park, Jin Young Kim, Yoon Ji Choi, Byeong Seok Sohn et al. · 2024 · Cancer Research and Treatment
  100. Lipid-based drug delivery for lungs cancer
    Mohd Sayeed Shaikh, Rupesh R. Kurhade, Shaikh Shahbaz A. Majeed, Jaiprakash Navnath Sangshetti, Md. Faiyazuddin · 2025 · Elsevier eBooks